UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

VolitionRx Limited (NYSE:VNRX) Q3 2021 Results Conference Call November 11, 2021 8:00 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Tom Butera - Chief Executive Officer of Volition Veterinary Diagnostics Development Conference Call Participants Bruce Jackson - The Benchmark Company Steven Ralston - Zacks Michael Okunewitch - Maxim Group Operator Good morning, ladies and ...

Financial Performance - Total revenues for the three months ended September 30, 2021, were $25,483, compared to $575 for the same period in 2020, representing a significant increase [23]. - Product revenues for the nine months ended September 30, 2021, reached $75,795, up from $4,201 in the same period of 2020, indicating a growth of approximately 1,703% [23]. - Net loss for the nine months ended September 30, 2021, was $18,881,555, compared to a net loss of $15,238,380 for the same period in 2020, representing an increase of approximately 24% [33]. - Net loss for the three months ended September 30, 2021, was $7.2 million, compared to a net loss of $4.3 million for the same period in 2020, an increase of 66% [163]. - Total revenues for the nine months ended September 30, 2021, were $75,795, compared to $6,313 for the same period in 2020, representing an increase of over 100% [166]. Expenses - Operating expenses for the three months ended September 30, 2021, totaled $7,587,775, compared to $4,504,995 for the same period in 2020, reflecting an increase of 68% [25]. - Research and development expenses increased to $4.4 million for the three months ended September 30, 2021, from $3.2 million for the same period in 2020, a rise of 40% [156]. - General and administrative expenses rose to $2.4 million from $1.1 million year-over-year, an increase of over 100% [158]. - Sales and marketing expenses increased to $0.7 million from $0.2 million for the same period, also an increase of over 100% [160]. - Research and development expenses for the nine months ended September 30, 2021, were $12.0 million, up from $10.6 million in 2020, an increase of 13% [168]. - General and administrative expenses increased to $6.1 million from $4.3 million year-over-year, a rise of 41% [170]. - Sales and marketing expenses for the nine months ended September 30, 2021, were $1.6 million, compared to $0.7 million in 2020, an increase of over 100% [172]. Cash and Assets - Cash and cash equivalents as of September 30, 2021, were $22,901,784, an increase from $19,444,737 as of December 31, 2020 [19]. - Total assets as of September 30, 2021, were $30,003,579, compared to $26,150,553 as of December 31, 2020, marking an increase of 15% [19]. - Cash and cash equivalents as of September 30, 2021, totaled approximately $22.9 million, an increase from $20.9 million at the end of the previous year [40]. - The accounts receivable balance as of September 30, 2021, was $19,566, with no allowance for doubtful debts recorded, indicating minimal risk of uncollectibility [41]. Liabilities and Equity - Total liabilities decreased to $8,822,993 as of September 30, 2021, from $9,856,835 as of December 31, 2020, a reduction of approximately 10.5% [20]. - The total stockholders' equity as of September 30, 2021, was $21,180,586, an increase from $16,293,718 as of December 31, 2020, reflecting a growth of 30% [21]. - The total long-term debt payable as of September 30, 2021, was $2,787,389, with remaining payments of $281,249 in 2021 and $761,541 in 2022 [112]. Capital and Financing - The company issued common stock for net proceeds of $21,436,571 during the nine months ended September 30, 2021, compared to $19,200,954 in the same period of 2020, marking an increase of about 11.6% [34]. - The company raised approximately $18.9 million from an underwritten public offering of 3,809,524 shares at a price of $4.9533 per share on February 12, 2021 [69]. - Net cash provided by financing activities was $20.8 million for the nine months ended September 30, 2021, an increase from $18.5 million in the same period in 2020, driven by $18.9 million in net cash received from a registered public offering [147]. Operational Challenges - The ongoing COVID-19 pandemic has caused disruptions that may impact clinical trials, including delays in patient enrollment and sample collection [51]. - The Company has incurred losses totaling $129.0 million since inception, raising substantial doubt about its ability to continue as a going concern for at least one year from the issuance date of the financial statements [54]. - The company has not attained profitable operations and is dependent on obtaining external financing to continue its operational and strategic plans, raising substantial doubt about its ability to continue as a going concern [176]. Internal Controls and Compliance - The company has identified material weaknesses in its internal control over financial reporting, which were not effective as of September 30, 2021 [185]. - Remediation steps have been implemented, including hiring a full-time Business Controller and a financial planning and analysis manager to improve internal controls [188]. - The management has concluded that disclosure controls and procedures were not effective due to material weaknesses identified [185]. - The company intends to take additional steps to strengthen the control environment and address material weaknesses [191]. Research and Development - The company is developing a suite of low-cost Nu.Q immunoassays for various applications, including cancer diagnosis and monitoring [141]. - The company plans to expand its research and development capabilities by opening a laboratory in San Diego, California [141]. - The company is in the process of developing additional veterinary products, including a treatment monitoring test and a disease recurrence test [141].

Volition© 2021 August 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "ant ...

VolitionRx Limited (NYSE:VNRX) Q2 2021 Results Conference Call August 12, 2021 8:00 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Thomas Butera - Chief Executive Officer of Volition Veterinary Diagnostics Development Conference Call Participants Bruce Jackson - Benchmark Company Nathan Weinstein - Aegis Capital Steven Ralston - Zacks Investment Research Michael Okunewitc ...

Volition© 2021 August 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "ant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Volition© 2021 May 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "antici ...

VolitionRx Limited (NYSE:VNRX) Q1 2021 Results Conference Call May 12, 2021 8:00 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Conference Call Participants Kyle Mikson - Cantor Fitzgerald Bruce Jackson - Benchmark Company Jason McCarthy - Maxim Group Nathan Weinstein - Agesi Capital Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Voliti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (State or other jurisdiction of incorporation or organization) 91-1949078 (I.R.S. Employer Identification No.) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIO ...